Akebia Therapeutics Inc AKBA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.94
- Day Range
- $0.90–0.97
- 52-Week Range
- $0.88–4.08
- Bid/Ask
- $0.93 / $0.94
- Shares Outstanding
- 268.26M
- Market Cap
- $250.98M
- Volume/Avg
- 2M / 4M
Key Statistics
- Price/Earnings (Normalized)
- 277.78
- Price/Sales
- 1.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 194
- Website
- https://www.akebia.com
Valuation
|
Metric
|
AKBA
|
|---|---|
Price/Earnings (Normalized) | 277.78 |
Price/Book Value | 9.15 |
Price/Sales | 1.07 |
Price/Cash Flow | 6.40 |
Price/Earnings
AKBA
Financial Strength
|
Metric
|
AKBA
|
|---|---|
Quick Ratio | 1.30 |
Current Ratio | 1.40 |
Interest Coverage | 0.11 |
Quick Ratio
AKBA
Profitability
|
Metric
|
AKBA
|
|---|---|
Return on Assets (Normalized) | 0.45% |
Return on Equity (Normalized) | 5.10% |
Return on Invested Capital (Normalized) | 27.12% |
Return on Assets
AKBA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Cmshhwzwjs | Npvdn | $69B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Yctpdyfqrj | Bmzfkhb | $40B | |||
| Haleon PLC ADR
HLN
| Zkqmlpxnn | Txdn | $40B | |||
| Zoetis Inc Class A
ZTS
| Bchjtkxnqg | Tkd | $33B | |||
| Viatris Inc
VTRS
| Tccgwgjv | Sgf | $18B | |||
| Elanco Animal Health Inc
ELAN
| Stsm | Wcmt | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Mwggqcfh | Pvm | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Txgvxbt | Grdh | $6B | |||
| Curaleaf Holdings Inc
CURLD
| Cymcrsm | Ngqg | $3B | |||
| Prestige Consumer Healthcare Inc
PBH
| Kdxpycblr | Dykjprw | $2B |
United States